Remission induction in newly diagnosed AML patients aged 55-75 years using a 5 day idarubicin schedule in combination with cytarabine

被引：0
|
作者：
Douer, D
Saven, A
Watkins, K
Gollard, R
Kahn, A
Piro, L
Levine, AM
机构：
[1] UNIV SO CALIF,DIV HEMATOL,LOS ANGELES,CA
[2] SCRIPPS CLIN & RES FDN,DIV HEMATOL,LA JOLLA,CA 92037
来源：
BLOOD | 1995年 / 86卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3015 / 3015
页数：1
相关论文
共 37 条
  • [21] PHASE II PILOT TRIAL OF GEMTUZUMAB OZOGAMICIN (MYLOTARG) IN COMBINATION WITH FLUDARABINE, CYTARABINE, IDARUBICIN (FLAI) AS INDUCTION THERAPY IN CD33-POSITIVE AML PATIENTS YOUNGER THAN 65 YEARS
    Candoni, A.
    Martinelli, G.
    Tiribelli, M.
    Simeone, E.
    Toffoletti, E.
    Michelutti, A.
    Chiarvesio, A.
    Malagola, M.
    Piccaluga, P. P.
    Russo, D.
    Fanin, R.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 17 - 17
  • [22] Clofarabine and clofarabine plus low-dose cytarabine (ara-C) as induction therapy for patients (pts) ≥ 60 years with newly diagnosed acute myeloid leukemia (AML)
    Faderl, S
    Ravandi, F
    Ferrajoli, A
    Garcia-Manero, G
    Estrov, Z
    Thomas, DA
    O'Brien, S
    Verstovsek, S
    Wierda, W
    Cortes, J
    Giles, FJ
    Kwari, M
    Jarmon, R
    Kantarjian, HM
    [J]. BLOOD, 2005, 106 (11) : 786A - 786A
  • [23] High-dose cytarabine and idarubicin induction produces a high complete remission (CR) rate in previously untreated de novo acute myeloid leukemia (AML) patients (pts) ≥ 60 years old.
    Baer, MR
    Pixley, LA
    Ford, LA
    Donohue, K
    O'Loughlin, KL
    Minderman, H
    Block, AW
    Wetzler, M
    Slack, JL
    Herzig, GP
    Bloomfield, CD
    [J]. BLOOD, 2000, 96 (11) : 322A - 322A
  • [24] Gemtuzumab ozogamicin in combination with attenuated dose of standard induction chemotherapy therapy can successfully induce complete remission without increasing toxicity in patients with newly diagnosed acute myeloid leukemia aged 55 or older.
    Eom, Ki-Seong
    Kim, Hee-Je
    Min, Chang-Ki
    Lee, Seok
    Kim, Sung-Yong
    Cho, Byung-Sik
    Cho, Seok-Goo
    Kim, Dong-Wook
    Lee, Jong-Wook
    Min, Woo-Sung
    Park, Chong-Won
    Kim, Chun-Choo
    [J]. BLOOD, 2006, 108 (11) : 561A - 561A
  • [25] Optimization of idarubicin and cytarabine induction regimen with homoharringtonine for newly diagnosed acute myeloid leukemia patients based on the peripheral blast clearance rate: A single-arm, phase 2 trial (RJ-AML 2014)
    Zhang, Yunxiang
    Li, Xiaoyang
    Weng, Xiangqin
    Shen, Yang
    Chen, Yu
    Zheng, Yu
    Zhao, Huijin
    You, Jianhua
    Mao, Yuanfei
    Wang, Lining
    Wu, Min
    Sheng, Yan
    Wu, Jing
    Hu, Jiong
    Chen, Qiusheng
    Li, Junmin
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (01) : 43 - 51
  • [26] Quizartinib prolongs Life compared to Placebo plus intensive Induction Therapy and Consolidation Therapy followed by Monotherapy Treatment in Patients aged 18-75 Years with newly diagnosed FLT3-ITD and AML
    Schlenk, R.
    Montesinos, P.
    Vrhovac, R.
    Patkowska, E.
    Kim, H. -J.
    Zak, P.
    Wang, P. -N.
    Mitov, T.
    Hanyok, J.
    Liu, L.
    Benzohra, A.
    Lesegretain, A.
    Cortes, J.
    Perl, A.
    Sekeres, M.
    Dombret, H.
    Amadori, S.
    Wang, J.
    Levis, M.
    Erba, H.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 67 - 67
  • [27] Farnesyl transferase inhibitor (tipifarnib, zarnestra; Z) in combination with standard chemotherapy with idarubicin (Ida) and cytarabine (ara-c) for patients (pts) with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)
    Cortes, J
    Garcia-Manero, G
    O'Brien, S
    Verstovsek, S
    Estrov, Z
    Giles, F
    Ravandi, F
    Wright, J
    Kantarjian, H
    [J]. BLOOD, 2005, 106 (11) : 784A - 784A
  • [28] Phase 2B Randomized Study of CPX-351 Vs. Cytarabine (CYT) plus Daunorubicin (DNR) (7+3 Regimen) In Newly Diagnosed AML Patients Aged 60-75
    Lancet, Jeffrey E.
    Cortes, Jorge E.
    Hogge, Donna E.
    Tallman, Martin
    Kovacsovics, Tibor
    Damon, Lloyd E.
    Ritchie, Ellen
    Komrokji, Rami S.
    Louie, Arthur C.
    Feldman, Eric J.
    [J]. BLOOD, 2010, 116 (21) : 286 - 287
  • [29] A phase 3, randomized study of pracinostat (PRAN) in combination with azacitidine (AZA) versus placebo in patients ≥18 years with newly diagnosed acute myeloid leukemia (AML) unfit for standard induction chemotherapy (IC).
    Garcia-Manero, Guillermo
    Fong, Chun Yew
    Venditti, Adriano
    Mappa, Silvia
    Spezia, Riccardo
    Ades, Lionel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] Feasibility, safety and efficacy of gemtuzumab ozogamicin followed by intensive chemotherapy for remission induction in previously untreated patients with AML aged 61-75 years: Update of a phase II trial of the EORTC Leukemia Group and GIMEMA.
    Amadori, S
    Willemze, R
    Suciu, S
    Mandelli, F
    Selleslag, D
    Stauder, R
    Ho, AD
    Denzlinger, C
    Leone, G
    Fabris, P
    Muus, P
    Fiengold, J
    Beeldens, F
    Anak, O
    De Witte, TM
    [J]. BLOOD, 2002, 100 (11) : 340A - 340A
1234